DelMar Pharmaceuticals (NASDAQ:DMPI) Cut to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of DelMar Pharmaceuticals (NASDAQ:DMPI) from a hold rating to a sell rating in a research report report published on Thursday morning, Zacks.com reports.

According to Zacks, “DelMar Pharmaceuticals, Inc. is involved in developing drug for orphan cancer indications. DelMar Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “

A number of other research analysts have also weighed in on DMPI. ValuEngine lowered shares of DelMar Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 2nd. Maxim Group began coverage on shares of DelMar Pharmaceuticals in a research report on Friday, September 6th. They set a buy rating for the company. Finally, Dawson James reissued a buy rating on shares of DelMar Pharmaceuticals in a research report on Thursday, July 11th.



DelMar Pharmaceuticals stock opened at $0.60 on Thursday. DelMar Pharmaceuticals has a fifty-two week low of $0.55 and a fifty-two week high of $8.50. The firm has a fifty day moving average price of $0.94 and a two-hundred day moving average price of $1.14.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.

Further Reading: How does a security become overbought?

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.